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ARTICLE
CGG-Repeat Expansion in the DIP2B Gene Is Associated
with the Fragile Site FRA12A on Chromosome 12q13.1
Birgitta Winnepenninckx,* Kim Debacker,* Jacqueline Ramsay, Dominique Smeets, Arie Smits,
David R. FitzPatrick, and R. Frank Kooy
A high level of cytogenetic expression of the rare folate-sensitive fragile site FRA12A is significantly associated with mental
retardation. Here, we identify an elongated polymorphic CGG repeat as the molecular basis of FRA12A. This repeat is
in the 5′ untranslated region of the gene DIP2B, which encodes a protein with a DMAP1-binding domain, which suggests
a role in DNA methylation machinery. DIP2B mRNA levels were halved in two subjects with FRA12A with mental
retardation in whom the repeat expansion was methylated. In two individuals without mental retardation but with an
expanded and methylated repeat, DIP2B expression was reduced to approximately two-thirds of the values observed in
controls. Interestingly, a carrier of an unmethylated CGG-repeat expansion showed increased levels of DIP2B mRNA,
which suggests that the repeat elongation increases gene expression, as previously described for the fragile X–associated
tremor/ataxia syndrome. These data suggest that deficiency of DIP2B, a brain-expressed gene, may mediate the neuro-
cognitive problems associated with FRA12A.
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The eukaryotic genome contains tissue-specific patterns of
cytosines covalently modified by the addition of a methyl
group.1 Of all CpG dinucleotides of the mammalian ge-
nome, 60%–90% are subject to this kind of epigenetic
modification. Most of the unmethylated CpG sites are lo-
cated in the promotor region of genes, where changes in
their methylation status are linked to long-term changes
in expression level of the underlying genes.2 Methylated
cytosines may be targeted by methyl-binding domains
of transcriptional repressors—which, on binding, recruit
members of chromatin-remodeling complexes—resulting
in the deacetylation of core histone proteins and tran-
scriptional silencing of the underlying gene.3
Methylation abnormalities have been linked to a broad
range of diseases.2 In tumor cells, the promotor regions
with a CpG island are often hypermethylated. This epi-
genetic change is found in every type of tumor and is as-
sociated with a loss-of-gene transcription.3 Alterations of
genomic imprinting or loss of imprinting has been shown
to play a pivotal role in malignant tumorigenesis; for
example, see the works of Robertson2 and Muller et al.4
Methylation defects of the DNA-methylation machinery
itself can also give rise to different human diseases. For
instance, mutations in the DNMT3B gene are known to
cause human immunodeficiency syndrome (ICF) (immu-
nodeficiency, centromeric heterochromatin, facial anoma-
lies, mental retardation, prolonged respiratory infections,
and infections of the skin and digestive system) because
of hypomethylation of the pericentromeric satellite DNA,
which causes centromeric decondensation and chromo-
somal rearrangements.5 In addition, faithful maintenance
of the DNA-methylation pattern and the enzymes that bind
methylated CpG residues are essential for proper function-
ing and survival of the CNS.6–8
Excessive DNA methylation may also be responsible for
gene silencing at rare folate-sensitive fragile sites. Fragile
sites are breakage-prone spots in the DNA that express
as gaps and breaks in chromosomes when cells are grown
in vitro under specific cell-culture conditions. Rare fragile
sites are further subdivided according to specific culture
conditions by which they are induced. Six folate-sensitive,
rare fragile sites have been characterized at the molecular
level—namely, FRAXA,9 FRAXE,10 FRAXF,11 FRA11B,12
FRA16A,13 and, more recently, FRA10A.14 All six were
shown to be associated with an expanded CGG repeat.
After repeat expansion, the CGG repeat and the surround-
ing CpG island located in the promotor become hyper-
methylated. Several of the rare folate-sensitive fragile sites
have been associated with cognitive dysfunction; for ex-
ample, fragile X syndrome, caused by expression of the
fragile site FRAXA, is characterized by mental retardation
and specific dysmorphic and behavioral features. Expan-
sion of the FRAXE repeat is associated with a mild form
of mental retardation. In vivo chromosome breakage at
or near the FRA11B locus has been implicated in Jacobsen
syndrome, characterized by mental retardation and spe-
cific associated abnormalities.
In the present study, we have cloned the fragile site
FRA12A, another rare folate-sensitive fragile site that has
been linked to mental retardation (for an overview, see
the work of Berg et al.15), and we have identified the as-
sociated gene. The protein product of the FRA12A-asso-
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Figure 1. Family pedigree of FRA12A-expressing families A–C
Figure 2. FISH mapping of BAC clone RP11-831J22, spanning
the fragile site FRA12A in patient I.1. The fragile site FRA12A is
indicated by an arrow.
ciated gene DIP2B contains a DMAP1-binding domain and
might thus be involved in DNA-methylation processes.
Subjects and Methods
Clinical Diagnosis and Chromosome Analysis
Family A.—The proband (III.1; fig. 1A) was a 5-year-old girl who
had global delay in her neurodevelopment during infancy, sig-
nificant learning disability, subtle craniofacial dysmorphisms, and
recurrent, inexplicable chest infections.15 She had bullous ichth-
yosiform erythroderma and areas of hyperkeratosis, particularly
around the knees, elbows, wrists, and neck. Both the mother (II.2;
fig. 1A) and the grandmother (I.2; fig. 1A) of the proband were
phenotypically unaffected. Examination of metaphase chromo-
some spreads from the proband revealed a fragile site at 12q13
in 8 of the 20 metaphases examined. An identical fragile site was
observed in metaphase chromosomes of the mother (4 of 20) and
the grandmother (4 of 40). After receipt of informed consent, a
peripheral-blood sample from the grandmother was obtained. Ep-
stein-Barr virus (EBV)–transformed lymphoblastoid cell lines of
the proband and her mother were obtained from the European
Collection of Cell Cultures.
Family B.—The proband (subject II.2; fig. 1B) was a 15-year-old
mentally retarded boy who had epileptic seizures and serious be-
havioral problems.16 A fragile site at 12q13 was seen in 20 of 50
of his metaphase chromosomes. His mother (subject I.2; fig. 1B)
and sister (subject II.1; fig. 1B) showed the same fragility in 13
of 50 and 11 of 50 of their metaphase chromosomes, respectively.
Yet they did not show any phenotypical abnormality. Peripheral-
blood samples from the proband and his mother were obtained,
with informed consent. From these peripheral-blood samples,
EBV-transformed lymphoblastoid cell lines were established at
our laboratory.
Family C.—Subject II.1 (fig. 1C) of this family was a 35-year-old
phenotypically unaffected man. The fragile site FRA12A was de-
tected in peripheral-blood cells with a frequency of 2 of 63 meta-
phases in standard low-folate medium.17 When we added metho-
trexate and BrdU to the standard medium, frequency was in-
creased to 11 of 50 metaphases. The addition of FudR also induced
the FRA12A site in fibroblast cells, with a frequency of 8 of 77
metaphases. Peripheral-blood cells of his mother also displayed
the site in standard medium (4 of 63 metaphases). Peripheral-
blood samples from subject II.1 were obtained after informed
consent, and we established an EBV-transformed lymphoblastoid
cell line. None of the children of subject II.1 inherited the FRA12A
fragile site.
FISH Mapping
Slides for FISH analysis were made from fixed cell suspensions of
subject I.1, by standard methods. BAC clone RP11-831J22 (Ros-
well Park Cancer Institute library) was obtained from the BACPAC
Resource Center. The probe was labeled with digoxigenin-11-2-
deoxyuridine 5-triphosphate (dUTP) or biotin-16-dUTP (Roche)
by nick translation. DNA hybridization and antibody detection
were performed in accordance with standard protocols. At least
five metaphases were analyzed for each hybridization, with a Zeiss
Axioplan 2 fluorescence microscope equipped with a triple band-
pass filter (#83000 for 4,6-diamidino-2-phenylindole, fluorescein
isothiocyanate, and Texas Red [Chroma Technology]). Images were
collected using a cooled CCD camera (Princeton Instruments Pen-
tamax [Roper Scientific]) and were analyzed using IPLab software
(Scanalytics).
PCR Amplification and Hybridization
of the FRA12A-Associated CGG Repeat
PCR amplification of the normal allele of the FRA12A repeat–
containing region was performed with the aid of 2.5#PCR# En-
hancer solution (Invitrogen) with use of primers derived from the
sequences flanking the repeat (DIP2B-CGG-F primer, 5′-GTCTTC-
AGCCTGACTGGGCTGG-3′, and DIP2B-CGG-R, primer 5′-CCGG-
CGACGGCTCCAGGCCTCG-3′). To amplify the expanded allele,
a PCR with use of deaza-dGTP (2-deoxyguanosine5-triphosphate)
instead of common dGTP was performed as described by Sarafi-
dou et al.14 The expanded allele could not be detected on an
agarose gel. Therefore, the PCR products were electrophoresed on
a 1.5% agarose gel and, after denaturation and neutralization,
were transferred to Hybond N membranes. Hybridization was
performed at 65C with use of a 255-bp PCR CGG probe, produced
using primers DIP2B-CGG-F and DIP2B-CGG-R. Triplet-repeat
Table 1. Overview of FRA12A Expression of 41 Individuals from 16 Published Families
Family
and Subject Sex
MR/
Delaya
Percentage
of Cells
with
FRA12A
Expression Phenotype and Remarks Reference (Year)
1: Giraud et al.20 (1976)
1 F N Mother of baby with lethal arthrogryposis, baby had no evidence of FRA12A
(subject 9)
2: Giraud et al.20 (1976)
2 M Y Male with MR and multiple congenital abnormalities (not detailed) (subject 10)
3: Stetten et al.21 (1988)
3 F N Woman, aged 38 years, with two miscarriages
4: Smeets et al.16 (1985)
4 M Y 40 Male with MR (40% of cells), unaffected sister (22% of cells), and
unaffected mother (26% cells)
5 F N 22 Unaffected sister of subject 4
6 F N 26 Unaffected mother of subject 4
5: Moric-Petrovic and Laca22 (1984)
7 M Y Male with MR, hypotonia, cryptorchidism, and micropenis; neither parent had
fragile site
6: Donti et al.23 (1979)
8 F Y 30 Female with MR, hypotonia, facial dysmorphisms, arachnodactyly,
intracranial calcification; neither parent had fragile site
7: Mules et al.17 (1983)
9 M N Incidental finding in the father of child with ring chromosome 13
10 F N 8 Mother of subject 9; low-folate culture failed, 4 of 63 FRA12A seen on stan-
dard-culture cultured fibroblasts 2 of 63 in subject 9
8: Sutherland and Hecht24 (1985)
11 M N 13 Phenotypically unaffected male neonate
12 F N 14 Phenotypically unaffected mother of subject 11
13 F N 24 Phenotypically unaffected maternal grandmother of subject 11
14 M N 12 Phenotypically unaffected maternal great-grandfather of subject 11
9: Sutherland and Hinton25 (1981)
15 M N 16 Found in family with autosomal dominant epidermylosis bullosa simplex (EBS),
unaffected
16 M N 16 Brother of subject 15; unaffected with EBS
17 F N 16 Sister of subject 15; affected with EBS
18 F N 28 Mother of subject 15; affected with EBS
19 F N 12 Maternal aunt of subject 15
20 F N 18 Maternal first cousin of subject 15
21 M N 30 Maternal first cousin of subject 15
22 F N 14 Maternal aunt of subject 15; unaffected with EBS
23 F N 11 Maternal first cousin of subject 15
24 F N 12 Maternal grandmother of subject 15; affected with EBS
25 M N 8 Maternal great-uncle of subject 15
10: Kumar et al.26 (1986)
26 F N 30 Probably incidental finding in a woman with craniofrontonasal dysplasia
27 F N 27 Unaffected sister of subject 26
28 F N 20 Mother of subject 26; also affected with craniofrontonasal dysplasia
11: Webb et al.27 (1987)
29 F Y Female with mild nondysmorphic MR; parents not available
12: Guichaoua et al.28 (1982)
30 F N Mother of an infant with multiple malformations
13: Guichaoua et al.28 (1982)
31 M Y Male, aged 7 years, with dysmorphic features
14: Giardino29 (1990)
32 M N 9 Male whose wife had multiple miscarriages
33 F N 14 Unaffected daughter of subject 32
34 F N 16 Unaffected daughter of subject 32
15: Kahkonen30 (1989)
35 F N 25 Unaffected female; coincidental finding on investigation of familial t(X;5)
36 F N 12 Unaffected mother of subject 35
37 F N 18 Unaffected maternal aunt of subject 35
38 M N 10 Unaffected maternal uncle of subject 35
16: Berg et al.15 (2000)
39 F Y 40 Girl, aged 11 years, with MR, pulmonary stenosis, and bullus ichthyosiform
erythroderma
40 F N 20 Mother of subject 39; unaffected
41 F N 2 Maternal grandmother of subject 39; unaffected
a Mental retardation (MR) or developmental delay.
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Figure 3. Allele frequencies of the FRA12A-associated 5′ CGG
repeat in a population of 70 control individuals.
Figure 4. Analysis of the DIP2B CGG repeat in controls (“C”) and
individuals expressing the FRA12A fragile site (in family B, subjects
I.2 and II.2; in family A, subjects I.2, II.2, and III.1). In addition
to a normal allele (“N”; 250 bp), individuals who cytogenetically
express the FRA12A site show additional PCR fragments of larger
size (“F”), indicating repeat expansion. The length of the expanded
allele in the unaffected FRA12A carriers (subjects I.2 and II.2 of
family A and subject I.2 of family B) is 650–850 bp. In the two
patients with FRA12A (subject III.1 of family A and subject II.2
of family B), the length of the expanded allele is 11,050–1,150
bp.
primed PCR was performed according to the principles described
by Warner et al.,18 to detect CAG-repeat expansion. We adapted
their protocol by using 2.5#PCR# Enhancer solution (Invitro-
gen), to be able to amplify the CGG repeat. Three different prim-
ers were added to the PCR mixture: a single forward fluorescently
labeled primer (DIP2B-CGG-F) and a combination of two reverse
primers (P4, 5′-TACGCATCCCAGTTTGAGACGGCCGCCGCCG-
CCGCCGC-3′, and P3, 5′-TACGCATCCCAGTTTGAGACG-3′) in a
1:10 ratio. The reverse primer P4 anneals at different sites of the
CGG repeat, which produces PCR products of different lengths
that differ from each other by a multiple of three residues. After
depletion of the P4 primer, the P3 primer takes over and amplifies
the PCR products of different lengths. PCR products were size
fractionated on a Prism ABI 3100 DNA sequencer (Applied Bio-
systems). The methylation status of the CGG repeat and the sur-
rounding region was analyzed by bisulphite sequencing. Ge-
nomic DNA was bisulphite treated using the EZ DNA methylation
kit (Baseclear). Bisulphite treatment converts all nonmethylated
cytosines into thymines, whereas methylated cytosines remain
unchanged. Primers specific for the methylated bisulphite–con-
verted DNA were developed (DIP2B-FM, 5′-GATAGATATATATTG-
TTAAGTTTAG-3′, and DIP2B-RM, 5′-CCGCCATAAACAAAAATC-
ACGTAAACG-3′). After PCR amplification, the CGG surrounding
area was sequenced using primers DIP2B-FM and DIP2B-RM on
a Prism ABI 3100 DNA sequencer (Applied Biosystems).
Gene-Expression Analysis
We used a multiple-tissue northern blot (FirstChoice Northern
Human Blot I [Ambion]) to determine the size of the DIP2B tran-
script. The specific DIP2B probe was an 855-bp cDNA PCR product
(forward primer, 5′-CCGCAGACACAAGAAACTGA-3′, located at
the exon 2–exon 3 boundary; reverse primer, 5′-AGCAGGAGGC-
CAGTTACAGA-3′, located in exon 8) and was radiolabeled by the
addition of [a-32P]dATP and [a-32P]dCTP (MP). Hybridization was
performed according to the manufacturer’s instructions. Detailed
information on the expression pattern of the DIP2B gene was
obtained from a multiple tissue expression (MTE) array (BD Bio-
sciences) that was hybridized to the radiolabeled 855-bp DIP2B
cDNA probe. Hybridization was performed according to the man-
ufacturer’s instructions.
The European Bioinformatics Institute (EBI) database was
searched for coding SNPs (cSNPs) within the coding sequence of
the DIP2B gene. The presence of cSNPs in the FRA12A carriers
and patients was tested by sequencing at the genomic level. RNA
was isolated for EBV-transformed lymphoblastoid cells of the
FRA12A carriers through use of Trizol (Invitrogen) and was con-
verted to cDNA through use of Superscript III reverse transcriptase
(Invitrogen). cDNA was tested for the presence of cSNPs in FRA12A
carriers and patients by PCR followed by sequencing. The follow-
ing primer sets were used: for exon 16, 5′-GATGCACACAATCAG-
CGTAC-3′ (forward) and 5′-TCAGGCTTCAGTCCATGACT-3′ (re-
verse); for exon 20, 5′-AATCTGTGTTAGCTCCAGAACT-3′ (for-
ward) and 5′-TCTACAGCCAATCCAGTAGC-3′ (reverse); for exon
24, 5′-CTCCACTAGGAGGAATCCAT-3′ (forward) and 5′-ACTGTA-
GGATCTCTGCCAGA-3′ (reverse); and, for exon 37, 5′-AGCGTCA-
TGATGCATTGTATG-3′ (forward) and 5′-CCAACGATGAGGTAAT-
GCTC-3′ (reverse). Big Dye Terminator sequencing was performed,
and sequencing products were analyzed using an ABI 3100 (Ap-
plied Biosystems) automated sequencer.
Real-time quantitative PCR was performed using gene-specific
Assays-on-Demand containing two PCR primers (forward and re-
verse) and a TaqMan MGB probe (FAM dye labeled), obtained from
Applied Biosystems. Seven independent control individuals were
included in the first experiment, and five control individuals in
the second experiment. PCR products were synthesized from RNA
samples first converted to cDNA, through use of the qPCR Mas-
termix Plus without UNG (Eurogentec). The reactions were run
on an ABI Prism 7000 sequence-detection system. The thermal
cycler conditions were 2 min at 50C and 10 min at 95C, followed
by 40 cycles at 95C for 15 s and 60C for 1 min. The raw fluo-
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Table 2. Overview of Methylation and
Disease Status of FRA12A-Expressing
Individuals
Family and Subject Methylation Status
A:
II.2 No Unaffected
III.1 Yes Affected
B:
I.2 Yes Unaffected
II.2 Yes Affected
C:
II.1 Yes Unaffected
Figure 5. A, Sequence of the DIP2B promotor region. All non-
CpG cytosines are indicated in dark blue; CpG cytosines are indi-
cated in green. B, Sequence of the DIP2B promotor after bisulphite
treatment in FRA12A-expressing individuals with a methylated CGG-
repeat expansion. All nonmethylated cytosines are converted into
thymines (blue), whereas methylated cytosines remain unchanged
(red). C, Sequence of the DIP2B promotor after bisulphite treatment
in FRA12A-expressing individuals with an unmethylated repeat ex-
pansion. All cytosines are converted into thymines (blue).
rescence data were analyzed using the Sequence Detection Soft-
ware (SDS [Applied Biosystems]). The SDS results were subse-
quently exported as comma-separated value files and were im-
ported into the relative quantification software qBase for further
analysis. For normalization of the quantitative expression values,
the geometric mean of three housekeeping genes (GAPD, UBC,
and YWHAZ)19 were used. The final results were checked by the
nonparametrical Mann-Whitney U test.
Sequencing the DIP2B Gene
All 38 exons of the DIP2B gene were PCR amplified at the genomic
level. All primers used for mutation analysis of the DIP2B gene
can be obtained from the authors on request. Big-Dye Sequencing
products were analyzed on an ABI 3100 (Applied Biosystems) au-
tomated sequencer.
Results
Cytogenetic Expression of FRA12A and Likelihood of Mental
Retardation
The percentage of cells expressing FRA12A on cytogenetic
analysis was available for 41 individuals from 16 published
families (table 1). In seven of the individuals with signifi-
cant neurocognitive problems, the average level of expres-
sion was 43.7% (95% CI 33.6%–54.8%). In two of these
individuals, the FRA12A expression was de novo; for three
individuals, information about the parents was not avail-
able; and the remaining two individuals with mental re-
tardation inherited the fragile site maternally, and approx-
imately half of the cells of the unaffected mother ex-
pressed FRA12A. The average level of FRA12A expression
in the individuals with FRA12A but without mental retar-
dation was 16.6% (95% CI 14.3%–19.0%). Thus, the per-
centage of cytogenetic expression is significantly associ-
ated with the clinical phenotype of the patients.
FISH Mapping of FRA12A
Through use of FISH experiments on metaphase chromo-
some spreads obtained from lymphoblastoid cells of pro-
band III.1 of family A (fig. 1A), a single BAC clone RP11-
831J22 (49080K–49260K) (National Center for Biotechnol-
ogy Information [NCBI]) spanning the fragile site FRA12A
was identified (fig. 2). Since all hitherto cloned folate-sen-
sitive rare fragile sites are caused by a CGG-repeat expan-
sion, the identified BAC clone was searched for CGG re-
peats. A single (CGG)7 repeat was identified, located in the
CpG island at the 5′ end of the Disco-interacting protein
2 homologue DIP2B gene (alternate names KIAA1463,
FLJ34278, and MGC104005). The DIP2B gene maps to
chromosome 12q13.12.
Analysis of the DIP2B CGG Candidate Repeat
PCR-based amplification of the DIP2B candidate CGG re-
peat in 70 controls—a total of 140 chromosomes—revealed
13 different alleles, with a range of 6–23 CGG-repeat units;
the most common allele contained 6 repeats (fig. 3). We
analyzed six individuals with cytogenetic expression of
the fragile site FRA12A (subjects I.2, II.2, and III.1 of family
A; subjects I.2 and II.2 of family B; and subject II.1 of
family C). A single CGG allele in the normal-size range
was identified in all FRA12A carriers through use of prim-
ers flanking the repeat and standard PCR techniques. Trip-
let-repeat primed–PCR analysis18 did show a characteris-
tic ladder on the fluorescence trace, with a periodicity of
3 bp, for all FRA12A-expressing individuals but not for
controls, which indicates repeat expansion (not shown).
Subsequent PCR amplification incorporating deaza-dGTP,
followed by Southern blotting and hybridization with use
of a CGG-repeat probe, confirmed the presence of an ex-
panded allele in all patients and carriers with FRA12A
(fig. 4). This experiment was repeated several times, with
comparable outcomes. All individuals expressing FRA12A
showed much larger PCR fragments, indicating CGG-re-
peat expansion. The length of the expanded allele in the
unaffected FRA12A carriers (subjects I.2 and II.2 of family
A and subject I.2 of family B) exceeded that in control
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Figure 6. Position of the three conserved domains in the DIP2B
protein.
Table 3. Percentage Identity among the Human DIP2B Protein and Other Homologous
Protein Sequences
Protein and Species Accession Number
Percentage
Identity
Protein similar to DIP2B:
Rattus norvegicus XP_235656 (GenBank) 97.5
LOC239667:
Mus musculus NP_766407 (GenBank) 96.1
Protein similar to DIP2B, partial:
Bos taurus XP_580943.1 (GenBank) 93.3
Macaca fascicularis BAC41762 (GenBank) 83.7
DIP2C:
H. sapiens NP_055789 (GenBank) 72.7
Disco-interacting protein 2 (DIP2) homologue:
M. musculus Q8BWT5 (UniProtKB/Swiss-Prot) 70.7
DIP2A:
H. sapiens NP_055966 (GenBank) 71.2
individuals (250 bp) by at least 400–600 bp. In the two
patients with FRA12A (subject III.1 of family A and subject
II.2 of family B), the length of the expanded allele ex-
ceeded the normal length by ∼800–900 bp.
To assess the methylation status of the expanded CGG
allele and the surrounding CpG island, a 304-bp region
of the promotor CpG island was subjected to bisulphite
sequencing. The Gene2Promotor program (Genomatix)
identified a 601-bp promotor region starting at 656 bp
before the start codon of the DIP2B gene. The FRA12A-
associated CGG repeat and the surrounding CpG island
lie within the predicted promotor. The bisulphite sequenc-
ing method allowed a detailed analysis of methylation in
a particular region by converting all nonmethylated cy-
tosines into thymines; methylated cytosines remained un-
changed. In control individuals, the promotor region was
unmethylated. In family A, this promotor region was fully
methylated in FRA12A-affected patient III.1 but was un-
methylated in the patient’s unaffected FRA12A-expressing
mother (subject II.2) and grandmother (subject I.2). In
family B, methylation of the 5′ promotor region of the
DIP2B gene was detected in FRA12A-affected patient II.2
and his FRA12A-carrier mother (subject I.2). Also in the
unaffected FRA12A carrier (subject II.1) of family C, the
promotor region was methylated (table 2). All cytosines
at CpG dinucleotides in the DIP2B promotor in the pa-
tients and carriers were methylated as indicated in figure
5.
DIP2B Protein
The DIP2B gene contains 38 exons, which encode a
putative 1,576-aa protein. The DIP2B gene is a mem-
ber of the Disco-interacting 2 family (Ensembl family
ENSF00000000904), which contains two additional mem-
bers: DIP2A on chromosome 21q22.3 and DIP2C on chro-
mosome 10p15.3. Percentage similarities, as calculated by
the program Align (EBI), are listed in table 3. The DIP2B
protein contains three putative functional domains: one
DMAP1-binding domain (location 14–131) and two AMP-
binding domains (locations 370–822 and 1025–1495) (fig.
6). The conserved domain database (NCBI) points out that
the DMAP1-binding domain is highly conserved through-
out the eukaryotic kingdom (fig. 7), an indication of its
important function.
DIP2B Gene Expression
For northern-blot analysis, we used a specific DIP2B probe
that contained exons 3–7. A single transcript of ∼9 kb,
which corresponds well to the predicted cDNA size, was
detected in several human tissues (fig. 8). DIP2B expres-
sion was found in brain, placenta, skeletal muscle, heart,
kidney, pancreas, lung, spleen, and colon. Hybridization
of an MTE array (data not shown) indicated that the DIP2B
gene is expressed in several brain regions: the cerebral
cortex; the frontal, parietal, occipital, and temporal lobes;
the paracentral gyrus; the pons; the corpus callosum; and
the hippocampus. Highest expression levels in the brain
were found in the cerebral cortex and the frontal and pa-
rietal lobes.
To detect possible differences in the expression levels of
DIP2B among FRA12A-affected patients, FRA12A carriers,
and control individuals, real-time PCR was performed. To
have a representative sampling, cDNA of each FRA12A car-
rier and patient was prepared three times independently,
and each preparation was analyzed in duplicate (fig. 9).
This procedure was repeated, with comparable results (ta-
ble 4). As expected, for both patients with FRA12A, DIP2B
expression was reduced to about half the amount of that
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Figure 7. A, Alignment of the six most similar homologues of the DMAP1-binding domain of the DIP2B protein. Amino acid–sequence
positions are indicated at the beginning and end of each line. Identical amino acids are indicated in red, and the similar ones in blue.
The source species and the accession number of the sequence are indicated at the left of each line. B, Percentage similarity among
the DIP2B DMAP1-binding domain and its homologues.
Figure 8. Northern-blot analysis of the DIP2B gene. A specific
cDNA probe was hybridized to a human multiple-tissue northern
blot. A single transcript of ∼9 kb was detected in various human
tissues.
in controls (55% [ ] and 45% [ ] in the firstPp .002 Pp .001
and second experiment, respectively). For subject II.2 of
family A, a carrier of an unmethylated FRA12A expansion,
real-time PCR results revealed enhanced expression values
(200% [ ) and 142% [ ]). Subjects I.2 ofPp .009 Pp .013
family B and II.1 of family C, both carriers of a methylated
FRA12A expansion, showed a reduction of DIP2B expres-
sion, approximately two-thirds of that of controls (67%
[ ] and 63% [ ]).Pp .056 Pp .001
To verify whether the reduced gene expression in pa-
tients with FRA12A is due to the silencing of the expanded
allele, cSNP analysis was performed by sequencing. Four
cSNPs were found in the DIP2B cDNA sequence (GenBank
accession number NM_173602): one at position 2073 in
exon 16 (c.2073A/T), one at position 2530 in exon 20
(c.2530A/G), one at position 3102 in exon 24 (c.3102T/
C), and one at position 4587 in exon 37 (c.4587C/T). All
FRA12A carriers and patients were tested for these cSNPs.
The cSNP in exon 16 appeared informative in DNA of
carrier I.2 of family B (genotype g.2073A/T). By sequenc-
ing the cDNA of subject I.2, only the c.2073A allele could
be detected, indicating the transcriptional silencing of the
T allele. Determination of the inheritance in family B dem-
onstrated that it is the FRA12A allele that is silenced: de-
scendant II.2 of carrier I.2 has the genotype g.2073T/T.
The fact that he expresses FRA12A indicates that the
c.2073T allele is linked to the CGG-repeat expansion.
Finally, all exons of the DIP2B gene were sequenced at
the DNA level, and intron/exon boundaries were checked
for both FRA12A-affected patients. No sequence alterations
could be detected in the DIP2B coding sequences.
Discussion
Our study provides evidence that the molecular basis of
the rare folate-sensitive fragile site FRA12A is a CGG-repeat
expansion at the 5′ end of the DIP2B gene. The DIP2B CGG
repeat was shown to be expanded in individuals express-
ing the FRA12A site. An expanded CGG repeat has also
been found in previously cloned folate-sensitive rare frag-
ile sites. The FRA12A CGG repeat, located in the CpG island
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Figure 9. Box plot showing the significant difference in the nor-
malized amount of RNA for DIP2B in function of the methylation
status and the disease status. Plot 1 represents control individuals,
plot 2 represents patients with a methylated repeat expansion,
plot 3 represents healthy individuals with a methylated repeat ex-
pansion, and plot 4 represents a healthy individual with an un-
methylated repeat expansion. The significance was tested using
one-way ANOVA (analysis of variance).
in the promotor region of DIP2B, is polymorphic in the
general population and is expanded on transmission to
the next generation in the FRA12A-affected families we
analyzed.
The putative DIP2B protein contains a highly conserved
DMAP1-binding domain and two AMP-binding domains.
The AMP-binding domains are rich in serine, threonine,
and glycine and possess a catalytic activity. The DNMT1-
associated protein (DMAP1) was discovered recently and
has a transcription-repressor activity.31 The chief enzyme
that maintains DNA methylation of the mammalian ge-
nome during S phase is DNA (cytosine-5)–methyltrans-
ferase 1 (DNMT1).32,33 The carboxy-terminal catalytic do-
main of DNMT1 has a strong affinity for hemimethylated
DNA and transfers methyl groups from S-adenosylmethio-
nine to cytosines in CpG regions, whereas the N-terminal
portion directs the enzyme to the replication foci. More
recently, it has been shown that the noncatalytic N-ter-
minal region of DNMT1 also forms a repressive transcrip-
tion complex consisting of DNMT1, the histone deacetylase
HDAC2, and the DNMT1-associated protein DMAP1. The
DMAP1-DIP2B interaction may modify the DNMT1 enzy-
matic activity to perform an effective repression by meth-
ylation. If this is the case, the methylation of the DIP2B
promotor is able to directly influence the DNMT1 meth-
ylation machinery itself.
The DIP2B protein is a member of the DIP2 protein
family. We demonstrated expression of DIP2B in the brain.
In situ hybridization of the mouse dip2 homologue sug-
gested that mdip2 may participate in defining the seg-
mental borders in the CNS and may have a role in pro-
viding positional cues for axon pathfinding and pattern-
ing.34 A Drosophila homologue of DIP2B, discovered by
the yeast-2-hybrid interaction–trap technique, is a protein
that interacts with the Drosophila disconnected (disco) gene
shown to be required for proper neuronal connections in
both the larval and adult visual system of Drosophila.35,36
For FRAXA, the most extensively studied folate-sensitive
rare fragile site, a clear-cut relationship exists in males
between fragile-site expression and disease. Patients with
fragile X express the FRAXA fragile site in vitro because
of large CGG-repeat expansions, which cause hypermeth-
ylation of the promotor region of the underlying FMR1
gene. These so-called full mutations originate from smaller
expansions of the FMR1 CGG repeat (premutations), which
are unmethylated and do not cause fragile X syndrome.
A comparable situation is described for family A, where a
repeat grows stepwise in three generations to a methylated
CGG-repeat expansion in the youngest generation. It is
tempting to speculate that the de novo gene silencing of
the DIP2B gene is causative of the mental retardation in
this patient. A relationship between fragile-site expression
and mental retardation was predicted, since patients with
cytogenetic FRA12A expression and mental retardation
expressed the fragile site in a significantly higher percent-
age of cells than did unaffected FRA12A carriers. However,
in family B, the unaffected mother of the patient (subject
I.2) has a methylated repeat expansion as well, which
could imply that the coexistence of DIP2B methylation
and the mental retardation in patient II.2 is purely coin-
cidental. However, it can also be speculated that disease
penetrance is not 100%. This phenomenon is also seen in
FRAXE mental retardation, where expansion and meth-
ylation of the CGG repeat in front of the FMR2 gene is
not always associated with mental retardation.37 Some evi-
dence of nonpenetrance is provided by investigation of
the DIP2B expression in our FRA12A-affected families; it
seems to suggest that gene expression in unaffected car-
riers is higher than in patients.
Other proteins involved in methylation metabolism
have been implicated in disease as well. Mutations in the
methyl-CpG binding protein 2 gene (MECP2) cause Rett
syndrome, a form of severe mental retardation in females.
MECP2 is a transcriptional repressor that binds to meth-
ylated CpG residues and forms chromatin remodeling com-
plexes with various transcriptional repressors.38–40 Absence
of the MECP2 protein in mice results in neurological ab-
normalities and premature death.41,42 Additional evidence
of the importance of the DNA methylation machinery for
the brain comes from studies on Dnmt1-knockout mice.
Normal mice contain surprisingly high levels of Dnmt1
in neurons,43–46 whereas absence of this enzyme in the
brain results in death shortly after birth.47 Moreover, in
brains containing both normal and Dnmt1-negative cells,
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Table 4. Relative DIP2B Expression for Families A, B, and C in
Comparison with That for Control Individuals for Two Independent Real-
Time PCR Analyses
Experiment and Subject(s)
Relative
Expression
(%) P
1:
Healthy individual with unmethylated repeat expansion 200 K.01
Affected individuals with methylated repeat expansion 55 K.01
Healthy individuals with methylated repeat expansion 67 ∼.05
2:
Healthy individual with unmethylated repeat expansion 142 .01
Affected individuals with methylated repeat expansion 45 K.01
Healthy individuals with methylated repeat expansion 63 K.01
the Dnmt1-negative cells are rapidly lost and mutant neu-
rons are quickly eliminated.47 Mutations in one of the
methyltransferases, the DNMT3B gene, causes ICF, in which
neurological abnormalities are also present.48 Finally, ad-
ditional suggestions for a link between DNA methyla-
tion defects and brain disorders come from the ATR-X
syndrome (a-thalassemia/mental retardation syndrome,
X linked), characterized by severe psychomotoric retar-
dation, characteristic facial features, genital abnormali-
ties, and a-thalassemia. It was shown that the syndrome
is caused by mutations in the ATR-X gene, resulting in
changes in the methylation pattern of several highly re-
peated sequences, including the rDNA arrays, a Y-specific
satellite, and subtelomeric repeats.49 More recently, the
ATR-X gene has also been shown to be involved in other
X-linked mental retardation syndromes.50,51
A second interesting finding, although based on a single
case, is the observation that the elongated, unmethylated
CGG repeat of carrier II.2 for family A has a 1.4–2-fold
overexpression of the DIP2B gene. This implies two-to-
threefold overexpression of the expanded allele, with the
assumption of unaffected expression of the unexpanded
allele. A similar situation is found in fragile X premutation
carriers, who have an enhanced expression of the FMR1
mRNA of unmethylated elongated repeats. Our data thus
suggest that CGG-repeat expansion in general may act as
a transcriptional enhancer. Males with premutation fragile
X alleles are at risk for a neurodegenerative disorder called
“FXTAS” (fragile X–associated tremor/ataxia syndrome).52
It would therefore be of interest to determine the pheno-
type of aged FRA12A carriers.
In conclusion, we report the identification of the mo-
lecular cause of the fragile site FRA12A. The associated
DIP2B gene possesses a DMAP1-binding domain and
might therefore be involved in the methylation machin-
ery. Our finding warrants further investigations of the pos-
sible role of the DIP2B gene in mental retardation.
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